oxonic acid has been researched along with Anasarca in 10 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 7.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
| " The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 3.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
| " affine extract was evaluated in an experimental model with potassium oxonate (PO) induced hyperuricemia in mice which was used to evaluate anti-hyperuricemia activity and xanthine oxidase (XO) inhibition." | 3.85 | Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis. ( Cheng, L; Hu, YJ; Li, LN; Liang, WQ; Liu, PG; Pu, JB; Xu, P; Yang, QQ; Zhang, HJ; Zhang, YQ; Zhou, J, 2017) |
| "Pancreatic cancer is frequently complicated by malignancies in other organs." | 1.39 | Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. ( Gabata, T; Ikeda, H; Ishikawa, D; Iwakami, S; Matsui, O; Mouri, H; Nanjo, S; Ohtsubo, K; Takamatsu, Y; Takeuchi, S; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, HJ | 1 |
| Li, LN | 1 |
| Zhou, J | 1 |
| Yang, QQ | 1 |
| Liu, PG | 1 |
| Xu, P | 1 |
| Liang, WQ | 1 |
| Cheng, L | 1 |
| Zhang, YQ | 1 |
| Pu, JB | 1 |
| Hu, YJ | 1 |
| Liang, G | 1 |
| Nie, Y | 1 |
| Chang, Y | 1 |
| Zeng, S | 1 |
| Liang, C | 1 |
| Zheng, X | 1 |
| Xiao, D | 1 |
| Zhan, S | 1 |
| Zheng, Q | 1 |
| Yang, TH | 1 |
| Yan, DX | 1 |
| Huang, XY | 1 |
| Hou, B | 1 |
| Ma, YB | 1 |
| Peng, H | 1 |
| Zhang, XM | 1 |
| Chen, JJ | 1 |
| Geng, CA | 1 |
| Ohtsubo, K | 1 |
| Ishikawa, D | 1 |
| Nanjo, S | 1 |
| Takeuchi, S | 1 |
| Yamada, T | 1 |
| Mouri, H | 1 |
| Yamashita, K | 1 |
| Yasumoto, K | 1 |
| Gabata, T | 1 |
| Matsui, O | 1 |
| Ikeda, H | 1 |
| Takamatsu, Y | 1 |
| Iwakami, S | 1 |
| Yano, S | 1 |
| Takashima, T | 1 |
| Mukai, H | 1 |
| Hara, F | 1 |
| Matsubara, N | 1 |
| Saito, T | 1 |
| Takano, T | 1 |
| Park, Y | 1 |
| Toyama, T | 1 |
| Hozumi, Y | 1 |
| Tsurutani, J | 1 |
| Imoto, S | 1 |
| Watanabe, T | 1 |
| Sagara, Y | 1 |
| Nishimura, R | 1 |
| Shimozuma, K | 1 |
| Ohashi, Y | 1 |
| Silva, CR | 1 |
| Fröhlich, JK | 1 |
| Oliveira, SM | 1 |
| Cabreira, TN | 1 |
| Rossato, MF | 1 |
| Trevisan, G | 1 |
| Froeder, AL | 1 |
| Bochi, GV | 1 |
| Moresco, RN | 1 |
| Athayde, ML | 1 |
| Ferreira, J | 1 |
| Makari, Y | 1 |
| Fujiwara, Y | 1 |
| Yasuda, T | 1 |
| Takiguchi, S | 1 |
| Kimura, Y | 1 |
| Yano, M | 1 |
| Monden, M | 1 |
| Liu, L | 1 |
| Inoue, H | 1 |
| Nakayama, H | 1 |
| Kanno, R | 1 |
| Kanno, M | 1 |
| Chang, YH | 1 |
| Bluestone, R | 1 |
| Hayashi, T | 1 |
| Hasegawa, H | 1 |
| Tanaka, G | 1 |
| Ohmae, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074] | Phase 2 | 48 participants (Anticipated) | Interventional | 2016-07-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for oxonic acid and Anasarca
| Article | Year |
|---|---|
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease | 2016 |
9 other studies available for oxonic acid and Anasarca
| Article | Year |
|---|---|
Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Chromatography, High Pressure Liquid; Disease M | 2017 |
Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice.
Topics: Animals; Antioxidants; Arthritis, Gouty; Disease Models, Animal; Drugs, Chinese Herbal; Edema; Flavo | 2019 |
Termipaniculatones A-F, chalcone-flavonone heterodimers from Terminthia paniculata, and their protective effects on hyperuricemia and acute gouty arthritis.
Topics: Anacardiaceae; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chalcone; Dose-Re | 2019 |
Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cecal Neoplasms; Drug Combinations; Edema; Humans; Hypo | 2013 |
The antinociceptive and anti-inflammatory effects of the crude extract of Jatropha isabellei in a rat gout model.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Biomarkers, Pharmacological; Disease | 2013 |
[Weekly administration of paclitaxel as a second-line chemotherapy for advanced and recurrent gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administration Schedu | 2004 |
The endogenous danger signal uric Acid augments contact hypersensitivity responses in mice.
Topics: Animals; B7-2 Antigen; CD40 Antigens; Chlorobenzenes; Dendritic Cells; Dermatitis, Contact; Drug Syn | 2007 |
Adjuvant polyarthritis. VI. Effect of oxonate-induced hyperuricemia on the development of acute inflammation, immune response and adjuvant arthritis.
Topics: Animals; Antibody Formation; Arthritis; Arthritis, Experimental; Cell Line; Diet; Edema; Immunity, C | 1981 |
[A 13-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 1996 |